Free tool
FAERS Monitor: Pregnyl
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 017692 or its brand name (Pregnyl, Gonadotropin, Chorionic). Reports on generic versions are filed under their own applications.
Reports
2,092
Serious
1,000
48% of reports
Hospitalization
593
Death reported
30
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- ovarian hyperstimulation syndrome520
- no adverse event226
- product dose omission issue134
- drug ineffective115
- product packaging quantity issue101
- product quality issue93
- product use in unapproved indication87
- inappropriate schedule of drug administration83
- off label use79
- ascites76
- product dose omission73
- abdominal distension71
- injection site pain71
- nausea68
- headache63
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2005 | 10 |
| 2006 | 6 |
| 2007 | 5 |
| 2008 | 10 |
| 2009 | 13 |
| 2010 | 11 |
| 2011 | 18 |
| 2012 | 45 |
| 2013 | 39 |
| 2014 | 73 |
| 2015 | 48 |
| 2016 | 66 |
| 2017 | 200 |
| 2018 | 118 |
| 2019 | 160 |
| 2020 | 149 |
| 2021 | 166 |
| 2022 | 258 |
| 2023 | 111 |
| 2024 | 169 |
| 2025 | 112 |
| 2026 | 303 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,067 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| ovarian hyperstimulation syndromeSignal | 520 | 2886.3 | 2644.3 | 1,163,419 |
| product packaging quantity issueSignal | 101 | 90.7 | 74.9 | 8,793 |
| ascitesSignal | 76 | 26.1 | 20.9 | 1,804 |
| no adverse eventSignal | 226 | 12.6 | 11.1 | 2,410 |
| inappropriate schedule of drug administrationSignal | 83 | 11.7 | 9.5 | 807 |
| product dose omissionSignal | 73 | 11.3 | 9.0 | 673 |
| product quality issueSignal | 93 | 6.9 | 5.6 | 465 |
| abdominal distensionSignal | 71 | 6.8 | 5.4 | 350 |
| product dose omission issueSignal | 134 | 4.6 | 3.9 | 377 |
| product use in unapproved indicationSignal | 87 | 3.5 | 2.9 | 157 |
| injection site painSignal | 71 | 2.3 | 1.9 | 53 |
| headache | 63 | 1.0 | 0.8 | 0 |
| off label use | 79 | 0.9 | 0.7 | 1 |
| drug ineffective | 115 | 0.9 | 0.7 | 2 |
| nausea | 68 | 0.9 | 0.7 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.